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Background: Coronary artery disease (CAD) patients are at risk for life-threatening ventricular arrhythmias (VA)
related to scar tissue. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) can accurately
identify myocardial scar extent. It has been shown that scar extent, particularly scar transmurality, percent scar and
scar mass, are associated with the occurrence of appropriate implantable cardioverter-defibrillator (ICD) therapy.
However, quantification of transmurality extent has never been studied. The purpose of our study was to evaluate
whether different methods quantifying scar transmurality, percent scar and scar mass (assessed with LGE-CMR) can
predict appropriate ICD therapy in CAD patients with a long term follow-up period.
Methods and results: We enrolled retrospectively 66 patients with chronic CAD referred for primary or secondary
preventive ICD implantation and LGE-CMR before ICD implantation. Using LGE-CMR, scar extent was assessed by
measuring scar mass, percent scar and transmural scar extent using four different methods. The median follow-up
duration was 41.5 months (interquartile range 22–52). The endpoint was the occurrence of appropriate device
therapy and occurred in 14 patients. Pre-ICD revascularization and transmural scar extent were significantly
associated with the study endpoint but the latter was especially highly dependent on the method used. Patients
with appropriate device therapy had also larger scar mass (29.6 ± 14.5 g vs 17.1 ± 8.8 g, p = 0.004), and larger
percent scar (15.1 ± 8.2% vs 9.9 ± 5.6%, p = 0.03) than patients without appropriate device therapy. In multivariate
analysis, scar extent variables remained significantly associated with the study end-point.
Conclusions: In this study of CAD patients implanted for primary or secondary preventive ICD, pre-ICD
revascularization and scar extent studied by LGE-CMR were significantly associated with appropriate device therapy
and can identify a subgroup of CAD patients with an increased risk of life-threatening VA. Depending of the
method used, transmural scar extent may vary significantly and needs further studies to obtain a validated and
consensual study method.
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Sudden cardiac death (SCD) is the most frequent cause
of death in patients with coronary artery disease (CAD)
[1]. Implantable cardioverter-defibrillator (ICD) implant-
ation is a recognized beneficial therapy to prevent SCD
related to ventricular arrhythmias (VA) in patients with
low left ventricular ejection fraction (LVEF). However,
identifying patients at high SCD risk remains a difficult
challenge. Assessment of altered LVEF is still considered
as the best discriminant factor of high risk SCD patients
with CAD [2]. However its predictive accuracy is
low [3]. Thus, many patients who receive ICD therapy in
the light of current guidelines will never benefit from
the device. Post hoc analysis of the MADIT II study
population showed that only 35% of the patients who
received an ICD for primary prevention receive appro-
priate device therapy during the first 3 years of follow-
up [4]. Accordingly, better selection criteria for ICD
implantation must be found.
Myocardial scar has been demonstrated as a substrate
for malignant reentrant VA that may underlie SCD [5].
Late gadolinium enhancement cardiovascular magnetic
resonance imaging (LGE-CMR) can accurately and re-
producibly identify myocardial scar tissue and its exten-
sion [6,7]. The amount, as well as the transmural extent
of myocardial scar tissue on LGE-CMR has been shown
to predict overall mortality in patients with CAD inde-
pendently of the LVEF [8,9] and thus may identify
patients at risk of SCD. However, uniformity in the ana-
lysis of the LGE-CMR parameters is lacking and the dif-
ferent methods proposed to quantify the scar are not
equivalent and seem poorly reproducible [10]. The most
robust and reproducible parameters to quantify scar ex-
tent and to predict appropriate device therapy, appeared
to be the scar transmurality and the amount of scar (per-
cent scar and scar mass) [10-13].
The purpose of this study was to evaluate whether dif-
ferent methods quantifying scar transmurality, percent
scar and scar mass (assessed with LGE-CMR) can pre-




The study was conducted in a retrospective observa-
tional manner in our cardiology department, at the Caen
University Hospital (Normandy, France) during a period
of 4 years (2006–2009), on 66 consecutive patients with
CAD who had undergone LGE-CMR prior to primary or
secondary ICD implantation. Ethical committee study
procedures were in accordance with the Declaration of
Helsinki. The study protocol did not require institutional
review board approval since the study was performed
retrospectively, only observational and patient data wereanonymized and only patients from the Caen University
Hospital Center (Caen, France) were included.
CMR
All patients were scanned on a dedicated 1.5 T CMR
scanner (Signa, GE Medical systems, Waukesha, WI)
using a cardiac 5-element phased-array receiver coil.
Images were acquired during breathholds of approxi-
mately 15 seconds using vector ECG gating. After initial
localizer sequences, a stack of steady-state free preces-
sion cine images were acquired in the short axis plane
from the level of the mitral valve annulus to the left
ventricular (LV) apex. Contrast-enhanced images were
acquired approximately 15 minutes after bolus injec-
tion of gadoterate meglumine, DotaremW 0.15 mmol/
kg (Guerbet, Aulnay-sous-Bois, France) using a stand-
ard 2-dimensional inversion recovery gradient-echo
sequence [14].
CMR image post-processing and data analysis
All analyses were performed by an experienced cardiolo-
gist blinded to patient history using the freely available
validated cardiovascular image analysis software package
Segment v1.9 (http://segment.heiberg.se) [15,16]. Short-
axis cine images were used to measure end-diastolic
volume, end-systolic volume, LV mass and LVEF by stand-
ard methods. Papillary muscles were regarded as part of
the ventricular cavity. Scar analysis was performed using
short axis LGE-CMR images. Endocardial and epicardial
LV borders as scar tissue were semi-automatically deli-
neated in each LV short-axis slice and then manually cor-
rected. We worked with a binary approach to characterize
scar tissue (normal myocardium vs. scar tissue). Three
aspects of scar were quantified: the percent scar (percent-
age of the total LV volume), the scar mass and the trans-
mural scar extent. The percent scar was calculated by
summing the absolute amount of hyperenhanced tissue
for all LV short-axis slices divided by the total amount of
LV tissue. The scar mass was obtained by multiplying the
percent scar by LV mass. For the transmural scar assess-
ment, we used four different methods: 1) “scar transmur-
ality area based” (STAB) based on the quantification of LV
surface reached; 2) “scar transmurality line based” (STLB)
based on the radial extent of late enhancement between
the endocardial and epicardial borders; 3) “weighted in-
farct transmurality” (WIT) based on the LV segment mass
reached weighted by pixel intensity to account for partial
volume effect [17]. These first three methods are normal-
ized by the segment AHA area and, consequently, lose
their spatial information of scar. We therefore used the
last method: 4) “spatial maximal scar transmurality”
(SMST) that picks up maximal transmurality in the sector
whereas the other three methods pick up different aspects
of average transmurality. This method considers only the
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healthy tissue (Figure 1). The rationale behind using 4
different methods to quantify transmurality was to dem-
onstrate that using the same term “transmurality” in dif-
ferent studies was not necessarily synonymous with
comparable results. For the four methods, the transmural
scar extent was split into quartiles (1–24%, 25–49%, 50–
74% and 75–100%) [11], and the number of LV segments
expressed in the standard American Heart Association
17-segment model [18]. For all methods, a presence of
scar ≥ 75% was defined as transmural. All measurements
were repeated in 18 patients by the same observer and by
a second observer, blinded to the results of the first
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Figure 1 Example of changing values in the same area of fibrosis dep
by the total area of the AHA segmentation lose the spatial concept o
normalize by the area retain spatial information (SMST). STAB indicate
weighted infarct transmurality; SMST, spatial maximal transmurality.ICD implantation and details
All patients received an ICD according to international
guidelines [19]. Some patients were eligible for cardiac
resynchronization therapy (CRT) and received a com-
bined CRT-D device as recommended [20]. All manufac-
turers were represented for either ICD (Lumax, Lexos,
Lumos, Biotronik; Vitality 2, Teligen, Boston Scientific;
Entrust, Virtuoso, Intrinsic, Medtronic Inc, Current, St
Jude Medical) or CRT-D device (Contak, Contak renewal,
Cognis, Boston Scientific [Natick, Mass, formerly Guidant
Corp]; Lumax, Biotronik [Berlin, Germany]; Maximo,
Concerto, InSync III and InSync Sentry, Medtronic Inc
[Minneapolis, Minn]; Epic, Promote, Atlas, or Atlas II,
St Jude Medical [St Paul, Minn]; Ovatio, Paradym, Sorin























ending on the method of calculation: algorithms that normalize
f transmurality (STAB, STLB and WIT), and algorithms that do not
s scar transmurality area based; STLB, scar transmurality line based; WIT,








Age, yrs 60 ± 10 64 ± 11 0.17
Male gender, n (%) 14 (100) 50 (96) 0.46




3 (21,4) 38 (73,1) < 0.001
Previous PCI, n (%) 3 (21.4) 26 (50) 0.056
Previous CABG, n (%) 0 (0) 14 (26.9) 0.029
ICD indication, n (%)
Primary prevention 11 (78.6) 40 (76.9) 0.90
Secondary prevention 3 (21.4) 12 (23.1) 0.90
NYHA functionnal
class
1.9 ± 0.7 2.0 ± 0.7 0.45
Hypertension, n (%) 3 (21.4) 25 (48.1) 0.07
Diabetes, n (%) 4 (28,6) 12 (23,1) 0.67
Device type, n (%)
ICD single chamber,
n (%)
11 (78.6) 30 (57.7) 0.15
ICD dual chamber,
n (%)
1 (7.1) 8 (15.4) 0.42








216 ± 8 217 ± 7 0.66
Medication, n (%)
Beta-blocker 14 (100) 52 (100) 1.00
ACE inhibitor or ATII
antagonist
14 (100) 50 (96.2) 0.46
Statin 13 (92.8) 49 (94.2) 0.85
Amiodarone 1 (7.1) 16 (30.8) 0.07
Diuretics 11 (78,7) 37 (71.1) 0.58
Aldosterone blockers 6 (42.9) 24 (46.1) 0.83
Aspirin or clopidogrel 14 (100) 51 (98.1) 0.60
QRS duration, ms 103 ± 24 117 ± 33 0.13
Left bundle branch
block, n (%)
4 (28.6) 23 (44.2) 0.29
Right bundle branch
block, n (%)
1 (7.1) 9 (17.3) 0.35
Follow-up, months 47 ± 18 41 ± 17 0.29
Continuous data are expressed as mean±SD and categorical data as n (%). MI
indicates myocardial infarction; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass grafting; ICD, implantable cardioverter-defibrillator;
NYHA, New York Heart Association; CRT-D, cardiac resynchronization therapy
defibrillator; ACE, angiotensin-converting enzyme; ATII, angiotensin II.
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from 171 ± 8/min to 217 ± 7/min with antitachycardia
pacing therapy (ATP) (burst and/or ramp) then shock
therapies. Arrhythmias faster than 217 ± 7/min were
assigned to the ventricular fibrillation (VF) zone with
maximal shocks as the first line therapy.
Follow-up, events and end-point
Follow-up started at ICD implantation. All patients were
followed 3 months after ICD implantation and then every
6 months. In our institution, some patients have a remote
management system but were still followed as out patients
every 6 months. Patients were instructed to contact
the clinic after experiencing an ICD discharge for an
additional visit. The median follow-up duration was
41.5 months (interquartile range 22–52). Appropriate ICD
therapy was defined as ATP and/or shock therapy for VT
or VF and was chosen as the study end-point. Appropriate
arrhythmia detection and discrimination was confirmed
by analysis of stored electrograms by two electrophysiolo-
gists blinded to the CMR analysis. When an appropriate
ICD therapy occurred, acute reversible causes (particularly
electrolyte disorders) and acute myocardial ischemia as a
trigger for arrhythmic events were ruled out by electrocar-
diogram, standard blood examination and negative tropo-
nin levels. ICD therapy was classified as inappropriate
when triggered by sinus or supraventricular tachycardia,
T-wave oversensing, or electrode dysfunction.
Statistics
Statistical analyses were performed on the R software ver-
sion 2.14.0 (R Development Core Team, Vienna, Austria).
Categorical variables were expressed as percentages (num-
bers) and compared using Fisher’s exact test between the
two groups (receiving an appropriate ICD therapy or not).
Continuous variables were presented as mean ± standard
derivation and were compared between the two groups
using a Student’s t test, or Mann–Whitney U test, if not
normally distributed. The associations between the prob-
ability over time of receiving an appropriate ICD therapy
and all clinical, electrocardiographic and CMR variables
present in Tables 1 and 2 were first assessed in univariable
Cox proportional hazards models (or by a log-rank test in
case of a categorical variable for which the Cox model did
not converge) but for the sake of clarity only significant
variables (and LVEF and amiodarone share their clinical
significance) are shown in Table 3. A multivariable model
was then constructed with the most significant scar and
clinical variables in the univariable analysis, respectively
the scar mass and any previous pre-ICD revascularization
as the covariable. We inserted only two covariables in the
multivariate model due to the small number of patients
receiving an appropriate ICD therapy (n = 14), and we
used only one scar variable in the multivariate model
Table 2 CMR variables
Appropriate device







1.6 ± 1.9 3.9 ± 6.5 0.20
CMR haemodynamic data
LVEF, % 20.8 ± 9 24.1 ± 8 0.076
LV EDV, ml 275 ± 74 245 ± 50 0.073
LV ESV, ml 214 ± 47 196 ± 42 0.16
LV mass, g 205 ± 63 183 ± 36 0.09
CMR-LGE
Percent scar, % 15.1 ± 8.2 9.9 ± 5.6 0.026
Scar Mass, g 29.6 ± 14.5 17.1 ± 8.8 < 0.005
Transmural scar extent
STAB method
Total, n 11.7 ± 3.8 10.4 ± 3.1 0.20
≤24%, n 5.6 ± 2.4 6.1 ± 2.4 0.45
25-49%, n 2.6 ± 1.7 2.3 ± 1.7 0.55
50-74%, n 2.0 ± 1.3 1.3 ± 1.3 0.09
≥75%, n 1.5 ± 1.9 0.7 ± 1.0 0.13
STLB method
Total, n 11.9 ± 3.9 10.5 ± 3.1 0.20
≤24%, n 5.7 ± 2.1 6.2 ± 2.3 0.51
25-49%, n 2.7 ± 1.7 2.3 ± 1.7 0.49
50-74%, n 2.2 ± 1.3 1.4 ± 1.2 0.031
≥75%, n 1.3 ± 1.7 0.6 ± 0.9 0.22
WIT method
Total, n 11.9 ± 3.9 10.5 ± 3.1 0.20
≤24%, n 7.9 ± 3.0 7.7 ± 2.4 0.99
25-49%, n 2.6 ± 2.1 2.1 ± 1.7 0.51
50-74%, n 1.3 ± 1.9 0.6 ± 0.8 0.53
≥75%, n 0.1 ± 0.3 0.1 ± 0.3 0.95
SMST method
Total, n 12.4 ± 3.4 10.6 ± 3.1 0.062
≤24%, n 0.6 ± 0.8 0.7 ± 0.8 0.61
25-49%, n 1.3 ± 1.4 1.2 ± 1.5 0.72
50-74%, n 1.4 ± 1.6 1.7 ± 1.4 0.36
≥75%, n 9.1 ± 3.3 6.9 ± 3.5 0.03
Data are expressed as mean±SD. "n" indicates the number of LV segments. LV
indicates left ventricular; LV EDV, LV end-diastolic volume; LV ESV, LV
end-systolic volume; LVEF, left ventricular ejection fraction; LV mass, left
ventricular mass; CMR-LGE, late gadolinium enhancement cardiac magnetic;
STAB, scar transmurality area based; STLB, scar transmurality line based; WIT,
weighed infarct transmurality; SMST, spatial maximal transmurality.
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and the different transmurality quantification method.
The best model was defined by the log-likelihood test. Un-
adjusted and adjusted hazard ratios (HR) with their corre-
sponding 95% confidence interval (CI) were reported. Wetherefore performed Receiver operator characteristic
(ROC) analyses on significant predictors. In all analyses, a




During the study period, 66 patients with new ICD
implants for CAD with a LGE-CMR prior to device im-
plantation were included. Their baseline characteristics
are shown in Table 1. Fifty-nine (89%) patients presented
as ST-elevation MI, 39 patients (66%) received thrombo-
lytic therapy and the other 20 patients (34%) were trea-
ted by primary percutaneous coronary intervention.
Fifty-one patients (78%) presented with an initial 0 TIMI
flow, 38 patients (58%) with a multivessel impairment
and 56 patients (85%) were successfully treated by per-
cutaneous coronary angioplasty. The median time frame
between LGE-CMR and the respective coronary ische-
mic event was 4 months (interquartile range 3–6) and
with ICD implantation was 3.4 ± 1.9 months. In all
patients LGE-CMR was performed to guide the need for
potential revascularization prior to ICD implantation in-
cluding an assessment of myocardial viability. If neces-
sary, a pre-ICD revascularization was performed before
ICD placement (with a mean time frame of 1.7 ±
0.3 months). For the 41 patients who had pre-ICD revascu-
larization, the LVEF did not significantly improve after
revascularization and so did not modify the ICD indication.
Follow-up and events
During a median follow-up of 41.5 months (interquartile
range 22–52), study endpoint criteria was met in 14
patients (21%) and 10 patients died (15%). Non-cardiac
death was reported in 2 patients (3%). Cardiac death oc-
curred in 8 patients (12%): 7 patients (11%) died of end-
stage heart failure and 1 patient (11%) died after heart
transplant complications. In patients with appropriate
ICD therapy, there was no significant difference between
primary (n = 11) and secondary (n = 3) prevention indi-
cation (p = 0.90). Appropriate device therapy occurred
21 ± 20 months after ICD implantation. Eight of the 14
patients (57%) who presented the study endpoint were
treated with ATP directly followed by shock or shock
therapy only. The remaining 6 patients (43%) were suc-
cessfully treated with ATP therapy only. The mean VT
heart rate was 212 ± 32 bpm.
CMR variables
CMR findings are listed in Table 2. All patients had evi-
dence of scar tissue on contrast enhanced CMR. The
mean distribution of the number of LV segments with
transmural (≥ 75%) scar was: STAB: 0.8 ± 1.3; STLB:
0.7 ± 1.1; WIT: 0.08 ± 0.3; SMST: 7.36 ± 3.6, the mean
Table 3 Cox analysis of clinical characteristics and CMR
variables for prediction of appropriate ICD therapy
Univariable analysis Multivariable analysis
Hazard Ratio
(95% CI)
p value Hazard Ratio
(95% CI)
p value





0.003 10.8 (2.1-53.6) 0.001
Amiodarone use 0.21 (0.0274-1.61) 0.13
CMR variables
LVEF 0.942 (0.869-1.02) 0.14
Percent scar 1.08 (1.02-1.16) 0.014
Scar mass 1.08 (1.04-1.12) 0.0001 3.15 (1.35-7.33) < 0.001
Transmural scar extent
STAB ≥75% 1.36 (1–1.83) 0.048
STLB ≥ 50% 1.33 (1.04-1.69) 0.022
SMST total 1.21 (1–1.45) 0.045
SMST ≥75% 1.18 (0.993-1.39) 0.06
MI indicates myocardial infarction; LVEF, left ventricular ejection fraction; STAB,
scar transmurality area based; STLB, scar transmurality line based; WIT,
weighed infarct transmurality; SMST, spatial maximal transmurality.
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20 ± 11 g. As demonstrated in Table 2, depending on
the method used, the transmurality quantification could
differ significantly.
The percent scar, the scar mass, the number of LV
segments with SMST ≥ 75% and the number of LV
segments with STLB ≥ 50% (3.5 ± 2.4 vs 2.0 ± 1.6,
p = 0.027) were significantly larger in patients who
received appropriate ICD therapy compared with those
who did not receive appropriate ICD therapy. For the
STAB, WIT and SMST methods, the number of LV seg-
ment with a transmural extent ≥ 50% was not different
between patients who did and did not met the study
end-point.AUC (Percent Scar) = 0.694
AUC (Scar Mass) = 0.749
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Figure 2 ROC curves of the univariate (panel A) and multivariate (panAll measurements were repeated in 18 randomized
patients by the same observer and by a second observer,
blinded to the results of the first analysis. The intraclass
correlation coefficient for scar extent quantification was
0.91 for intra-observer agreement and 0.73 for inter-
observer agreement (p < 0.001 for both), demonstrating
high reproducibility.
Predictors of appropriate ICD therapy
As shown in Table 3 and Figure 2, univariate variables
significantly associated with the study end-point were
the number of transmural (≥ 75%) scar segments studied
by the STAB method, number of segments with a scar
extent ≥ 50% studied by the STLB method, total number
of segments presenting scar studied by the SMST
method, the percent scar, the scar mass, and any previ-
ous pre-ICD revascularization. Notably, LVEF (p = 0.14),
QRS width (p = 0.14) and amiodarone use (p = 0.13)
were not associated with the study end-point.
In our multivariate models, we could only retain the
two most significant parameters due to our small study
population. We took as scar variables the scar mass and
the percent scar due to univariate analysis results. We
included the notion of revascularization since it was the
most strongly clinical parameter associated with appro-
priate device therapy (Table 3). Scar variables remained
strongly associated with the occurrence of appropriate
ICD therapy but the strongest association was with the
scar mass (HR 3.15; 95% CI 1.35-7.33; p < 0.001 and
HR 10.8; 95% CI 2.1-53.6; p = 0.001).
CMR scar and Kaplan-Meier analysis
Median values of scar variables significantly associated
with appropriate device therapy were used to individualize
the risk of appropriate ICD therapy in this population. For
the number of scar segments with transmural extent,AUC (Revascularization + Percent Scar) = 0.846
AUC (Revascularization + Scar Mass) = 0.848




















el B) Cox models.
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the STLB method. We chose the STLB method because it
presented the strongest association with the study end-
point. Appropriate ICD therapy occurred in 11 of 30
patients with > 2 segments with a scar extent ≥ 50%
compared with only 3 of 36 patients with ≤ 2 segments
(p = 0.005). For the entire study population, the negative
predictive value of ≤ 2 segments with a scar transmural
extent ≥ 50% was 92% and sensitivity was 79% and the
specificity 63%. For the scar mass (median value 20 g, 28
patients with a large scar mass > 20 g and 38 patients with
a small scar mass ≤ 20 g), 10 patients (36%) with a large
scar mass received appropriate ICD therapy compared
with only 4 patients (11%) with a small scar mass
(p = 0.01). The negative predictive value of a small scar
mass was 90%, the sensitivity 71% and the specificity 65%
for the entire study population. For the percent scar (me-
dian value 11%, 27 patients with a percent scar > 11% and
39 patients with a percent scar ≤ 11%), 9 patients (33%)
with a large extent of scar received appropriate ICD therapy
compared with only 5 patients (13%) with a small extent of
scar (p = 0.04). The negative predictive value of a small ex-
tent of scar was 87% for the entire study population.
Kaplan-Meier survival curves for appropriate ICD
therapy-free survival were calculated between patient
groups stratified by median scar indices (scar mass, percent
scar and number of transmural scar segments) (Figure 3).
Discussion
Patients with chronic CAD are at risk of developing car-
diovascular events and particularly VA, but different risk
profiles exist. Traditional clinical indicators such as
depressed LVEF, are still used to identify patients at risk
of SCD [21], however these markers have low predictive
values and many patients with an ICD will never benefit
from the implantation [4]. Finding new indicatorsFigure 3 Kaplan-Meier curve analysis in our population showing the
according the median value of the percent scar (panel A), scar mass (
transmurality line based extent ≥ 50% (panel C). AIT indicates appropri
left ventricuar segments.therefore remains a challenge. In our study, the only
clinical parameter statistically associated with the study
end-point is the notion of pre-ICD revascularization
(Table 3). This finding is consistent with data from the
literature. Indeed, the absence of pre-ICD revasculariza-
tion was demonstrated as a risk factor for SCD and VA
by Barsheshet et al [22]. In a multivariate analysis, they
demonstrated that patients without prior revasculariza-
tion had a 48% increased risk (p = 0.01) of VT/VF or
death. This indicates that in addition to the scar tissue,
myocardial region not revascularized before ICD im-
plantation may predispose to recurrent ischemia or hi-
bernation and could be an associated substrate for VA
occurrence. They also showed that the association be-
tween pre-ICD revascularization and arrhythmic risk
was similar among patients who underwent either
coronary artery bypass graft (CABG) or percutaneous
coronary intervention (PCI) as the last revascularization
procedure prior to enrollment. In our study, there was a
significant difference between PCI and CABG, but this
result must be interpreted in the light of our relatively
small cohort.
After a MI, scar tissue serves as an important substrate
for VA, based on a re-entry phenomenon [23]. Conse-
quently, assessment of scar extent by LGE-CMR could
be useful for risk stratification of CAD patients. In this
retrospective and observational study with long term fol-
low-up, we confirmed that indices of LV scar extent,
quantified by LGE-CMR, are associated with the occur-
rence of appropriate ICD therapy in CAD patients, inde-
pendently of LVEF. These results are consistent with
data in the literature. Scott et al. quantified myocardial scar
in a 64 patients study with a mean follow-up of 19 ± 10
months [11]. The mean number of myocardial segments
with transmural scar was 2.3 ± 2.1 and the mean percent
scar was 14 ± 10%. These two criteria were significantdifference in appropriate ICD therapy when patients are stratified
panel B) and transmurality extent assessed with the scar
ate ICD therapy; STLB, scar transmurality line based, “n” the number of
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0.02 respectively). These findings were also confirmed by
Boyé et al. in 52 patients with chronic MI referred for pri-
mary preventive ICD implantation [24]. Infarct size was sig-
nificantly larger in patients with appropriate device therapy
or death (24 ± 8 g vs 16 ± 12 g, p = 0.02). One reason
explaining that percent scar and scar mass are more signifi-
cant than the transmural extent could be that in patients
following MI, subsequent increases in infarct size correlate
closely with the transmural extent of infarction, so increases
in infarct size reflect increasing transmurality given the
same area at risk [25].Figure 4 Correlations between the four methods of scar transmuralit
to 17 left ventricular segments. STAB indicates scar transmurality area based
transmurality; SMST, spatial maximal transmurality.Quantitatively assessing infarct extent after MI has
been a challenge for many years due to its important
clinical implications. The concept of transmurality in
humans is supported by coronary perfusion which is
performed from the subepicardial to the subendocardial
regions, resulting in a variable and heterogeneous extent
in the myocardial wall in case of acute non-Q-wave MI
and excess vulnerability of the subendocardial region to
ischemia [26]. The goal during the following years was
to develop methods to assess infarct size in order to pre-
vent the development of myocardial injury following an
acute MI. In this sense, special attention was paid toy quantification. For each patient, there are 17 points corresponding
; STLB, scar transmurality line based; WIT, weighed infarct
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crosis is known to induce deleterious remodeling [27] by
loss of circular strain [28] that may itself be the cause of
congestive heart failure. LGE-CMR is rapidly becoming
the standard method due to its efficiency in detecting
and distinguishing viable and nonviable myocardium
[7,29]. To date, the transmurality concept is constantly
used to assess infarct extension and severity but our
understanding of transmurality is largely based on ani-
mal models [30,31] which may cause errors when trans-
posing to humans. It should also be noted that currently,
validation of methods to assess infarct size and trans-
murality after MI is limited [32] leading to mixed results
for the same term "transmurality". This problem is well
illustrated in our study. We observed a significant asso-
ciation between transmurality and appropriate ICD ther-
apy but this is highly dependent on the method used
(Table 2). The first 3 methods (STAB, STLB, WIT), by
studying scar transmurality with the same approach
based on normalization of the total area of the AHA
segmentation regardless of the spatial concept of trans-
murality, are therefore more sensitive for scar mass than
for transmurality. They tend to underestimate scar trans-
murality (most patients present a scar transmurality < 50%,
Table 2). Moreover, as we can see in Figure 4, these 3 para-
meters are strongly correlated (R ≥ 0.959 for all 17 seg-
ments, p = 0). Conversely, the fourth method, by studying
scar transmurality while considering spatial information, is
more a reflection of the transmurality as the scar mass and
therefore tends to detect considerable transmural damage
(most of patients present a scar transmurality ≥ 75%,
Table 2). In view of these results and the absence of consen-
sus about transmurality quantification, the study of scar
transmurality must remain a secondary endpoint in the
CMR evaluation and should not participate to the decision
of ICD implantation.
Recently, several studies abandoned the binary approach
of scar quantification (scar tissue vs normal myocardium)
and focused on the border zone around an infarct (peri-
infarct zone) also determined by LGE-CMR. These studies
have suggested that these parameters could be able to pre-
dict mortality, inducibility of VA, and the occurrence of
appropriate ICD therapy [11,33-35]. However, these para-
meters seem to be time consuming, relatively operator-
dependent, and are difficult to practice on a daily basis for
the risk stratification of CAD patients [10]. In 55 patients
and during a mean follow-up of 2 years, De Haan et al.
evaluated previously validated methods of scar assessment
by LGE-CMR in their ability to predict VA [10]. They sug-
gested that quantification of total scar size with the binary
approach (scar tissue vs. normal myocardium) is better
and sufficient for SCD risk stratification of CAD patients.
Moreover, in a recent experimental trial, Schuleri et al.
studied the temporal evolution of the peri-infarct zone.They showed that the peri-infarct zone is dynamic and
decreases over time and after a reperfused myocardial in-
farction [36].Limitation
This study was a unicenter observational trial, with a
relatively small sample size and a small number of ap-
propriate device therapies so the present conclusions re-
quire confirmation in larger cohort, prospective and
multicenter studies. Moreover, from a pragmatic point
of view, a cut-off value is needed to link scar extent to
the identification of patients who are most likely to
benefit from ICD implantation. Unfortunately, our study
design prevents this. We have not been able to compare
the extent of fibrosis in patients with primary and sec-
ondary prevention due to the small number of patients
with secondary prevention. Furthermore, this trial
included patients with CRT-D. Since biventricular pacing
may also diminish the susceptibility to VA [37], this may
have introduced a bias, although no significant differ-
ence was seen in the prevalence of CRT-D between the
patients with and without appropriate device therapy.
Finally, our sequences did not include coverage of the
entire myocardium (just 1 short axis slice was missing),
so we could possibly have missed small areas of scar.
Conclusion
In this single-center study of patients with CAD and
ICDs, we demonstrated a strong association between
myocardial scar extent characterized by LGE-CMR with
a binary approach (scar tissue vs. normal myocardium)
and appropriate ICD therapy, independently of LVEF.
Depending on the method used, transmural scar extent
can predict appropriate ICD therapy in CAD patients
but requires a validated and consensual study method.
We hypothesize that this patient population could bene-
fit from this study by using the scar extent to improve
risk stratification strategies in CAD wanting to receive
for an ICD.
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